Kymera Therapeutics develops targeted protein degradation medicines for immunological diseases as a clinical-stage biopharmaceutical company. News about KYMR commonly centers on oral small molecule degrader programs, including KT-621, a STAT6 degrader for Type 2 inflammatory diseases such as atopic dermatitis and asthma, and KT-579, an IRF5 degrader tied to inflammatory bowel disease biology.
Company updates also cover preclinical and clinical data presentations, FDA regulatory designations, collaboration activity involving degrader candidates such as KT-200, and periodic operating and financial results. Additional announcements include investor conference participation and shareholder voting matters.
Kymera Therapeutics (NASDAQ: KYMR) is set to present key findings at the 3rd Annual Targeted Protein Degradation Summit on Oct. 14 and 15. CEO Nello Mainolfi will deliver a keynote on the IRAK4 program and its role in treating conditions like hidradenitis suppurativa (HS) and atopic dermatitis (AD). The company emphasizes its innovative Pegasus platform, showcasing preclinical studies on pharmacokinetic/pharmacodynamic (PK/PD) relationships essential for clinical drug development. Significant results include elevated IRAK4 levels in diseased skin, highlighting the pathway's relevance in HS.
Kymera Therapeutics (NASDAQ: KYMR) presented interim data at the 5th Annual Symposium on Hidradenitis Suppurativa Advances, revealing insights from a non-interventional trial on IRAK4 expression in patients with hidradenitis suppurativa (HS) and atopic dermatitis (AD). The study highlighted the effectiveness of KT-474, an IRAK4-targeted protein degrader, in lowering IRAK4 levels in blood mononuclear cells. With a Phase 1 trial expected to start in 2021, these findings support the potential of IRAK4 degraders in treating HS and other inflammatory diseases, addressing a critical unmet medical need.
Kymera Therapeutics, a biopharmaceutical company focused on targeted protein degradation, announced that CEO Nello Mainolfi will present at the Morgan Stanley 18th Annual Global Healthcare Conference on September 16, 2020, at 5:00 p.m. ET. The presentation can be accessed via a live webcast on the company's website, with an archived version available for 90 days. Kymera's focus includes developing therapeutics that target difficult disease-causing proteins, specifically through its Pegasus platform, addressing immune-inflammatory diseases and tumors.
Kymera Therapeutics (NASDAQ: KYMR) announced the appointment of Pamela Esposito, PhD, and Jeff Albers, JD, to its Board of Directors. Both bring extensive biopharmaceutical experience, enhancing Kymera's leadership during a pivotal growth phase. Dr. Esposito has been instrumental in raising over $400M for Replimune's oncolytic therapies, while Albers led Blueprint Medicines through a successful IPO. Their expertise is expected to advance Kymera's strategic direction and innovative treatment options for cancer and autoimmune diseases.
Kymera Therapeutics (NASDAQ: KYMR) announced the closing of its upsized initial public offering, selling 9,987,520 common shares at $20.00 per share, yielding approximately $199.8 million in gross proceeds. This includes 1,302,720 shares purchased by underwriters' option. Additionally, Kymera completed a private placement of 676,354 shares to Vertex Pharmaceuticals, raising $13.5 million. Registration statements for these offerings were effective as of August 20, 2020. All shares were sold by Kymera, aimed at advancing targeted protein degradation therapeutics.